Aerpio Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aerpio Therapeutics, Inc. - overview
Established
2011
Location
Cincinnati, OH, US
Primary Industry
Pharmaceuticals
About
Aerpio Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for ocular diseases, particularly those related to vascular dysfunction. Their approach is centered on addressing unmet medical needs in this area. Founded in 2011, Aerpio Therapeutics, Inc.
is based in Cincinnati, US. The company specializes in the development of therapeutics targeting ocular conditions. In April 2014, the company completed its SERIES A funding round, raising USD 22. 00 mn, led by OrbiMed Advisors with participation from multiple investors including Athenian Venture Partners and Novartis Venture Fund.
The total amount raised by the company stands at USD 22. 00 mn, with a current valuation of USD 72. 11 mn. Joseph Gardner is the founder of Aerpio Therapeutics, and he has a history of entrepreneurial ventures in the biopharmaceutical sector.
Aerpio Therapeutics, Inc. engages in the development of premium pharmaceutical therapies aimed at treating ocular diseases, primarily focusing on conditions linked to vascular dysfunction. The company's unique offerings include innovative products that address significant medical needs in the ophthalmic field, contributing to improved patient outcomes. Revenue for Aerpio Therapeutics, Inc.
is primarily generated through the commercialization of its pharmaceutical products. The firm employs various pricing strategies, allowing for flexible access to its therapies, but specific financial details regarding revenue figures were not disclosed in the provided data. Aerpio Therapeutics, Inc. is focused on expanding its product line with upcoming therapies aimed at treating additional ocular diseases, leveraging recent funding from its SERIES A round completed in April 2014.
The company plans to utilize the USD 22. 00 mn raised to further develop its pipeline and enhance its market presence, targeting both North America and Europe for expansion. Strategic initiatives include increasing collaborations with research institutions and pharmaceutical partners to accelerate product development and access new markets.
Current Investors
Athenian Venture Partners, Venture Investors, Novartis Venture Fund
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals, Biomaterials
Website
www.aerpio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.